8-K/A: ENDRA Raises $4.9M, Launches Digital Asset Strategy

ENDRA Life Sciences Inc. announced a $4.9 million private placement to fund a new digital asset treasury strategy and its TAEUS liver device study, while also terminating its ATM sales agreement.

Summary

• Secured approximately $4.9 million in gross proceeds from a private placement offering of 744,340 shares (or prefunded warrants) and warrants to purchase 1,488,680 shares.
• The combined purchase price for each share/prefunded warrant and accompanying warrants was $6.57, with a director participant purchasing at $7.06.
• The majority of net proceeds will establish a Digital Asset Treasury (DAT) strategy, with a portion allocated to working capital and the pilot validation imaging study for the TAEUS liver device, capped at $750,000 from offering proceeds and $1 million total.
• Entered into an Amended and Restated Investment Management Agreement with Arca Investment Management, LLC to manage approximately $3.5 million of DAT assets, focusing on decentralized finance including $HYPE.
• Arca will receive annual fees of 1.25% to 1.75% of AUM and a performance fee of 10% to 15% of net total return, and was issued warrants to purchase 400,000 shares.
• Terminated the At-The-Market (ATM) Issuance Sales Agreement with Ascendiant Capital Markets, LLC, which allowed for sales of up to $6.2 million in common stock.
• Appointed Jeff Dorman, Chief Investment Officer of Arca, to the Digital Asset Advisory Board.
• The 2025 Annual Meeting of Stockholders is scheduled for December 9, 2025, virtually, with a record date of October 16, 2025, and revised stockholder proposal deadlines of October 27, 2025.

Sentiment

Score: 6

Explanation: The capital raise provides necessary funding and supports strategic initiatives like the DAT and TAEUS study. However, the significant dilution potential from warrants and the high-risk nature of the digital asset strategy introduce considerable uncertainty and volatility, balancing the positive aspects.

Positives

• Successfully raised approximately $4.9 million in gross proceeds through a private placement, strengthening the company's capital position.
• Established a Digital Asset Treasury (DAT) strategy, potentially diversifying assets and creating new growth avenues.
• Secured expert management for the DAT strategy through Arca Investment Management, LLC, and appointed Jeff Dorman to the Digital Asset Advisory Board.
• Allocated funds for the pilot validation imaging study of the TAEUS liver device, indicating continued development in its core medical technology.

Negatives

• The private placement involves the issuance of new shares and warrants, which could lead to significant dilution for existing shareholders if warrants are exercised.
• The DAT strategy, focusing on decentralized finance and digital assets like $HYPE, introduces exposure to volatile and speculative markets.
• The termination of the ATM agreement removes a flexible capital-raising option, though it was replaced by the private placement.
• Significant fees (1.25%-1.75% AUM plus 10%-15% performance fee) will be paid to Arca for managing the digital assets.

Risks

• The company's DAT strategy involves investing in digital assets, including $HYPE, which are subject to significant market volatility and regulatory uncertainty.
• The success of the DAT strategy is dependent on the performance of digital asset markets and Arca's investment management expertise.
• The exercise of warrants issued in the private placement could lead to substantial dilution for current shareholders.
• The company's ability to achieve its strategic objectives, including the success of the TAEUS liver device study, is subject to various operational and market risks.

Future Outlook

The company intends to use the majority of net proceeds from the offering to establish its digital asset treasury (DAT) strategy and a portion for working capital, including the pilot validation imaging study of its TAEUS liver device. The DAT strategy will focus on decentralized finance, including purchasing $HYPE. The company also plans to file a registration statement within thirty days of the offering's closing date for the resale of the issued securities.

Management Comments

• We intend to use the majority of net proceeds from the Offering to establish the Company's digital asset treasury (DAT) strategy, with a portion for working capital purposes including the pilot validation imaging study of the Company's TAEUS liver device.

Industry Context

This filing indicates ENDRA Life Sciences is diversifying its corporate treasury strategy by entering the digital asset space, a trend seen in some companies seeking alternative asset classes for treasury management, though less common for a medical device company. The focus on decentralized finance and specific digital assets like $HYPE suggests a higher-risk, higher-reward approach compared to traditional treasury management. Simultaneously, the continued funding for its TAEUS liver device study shows ongoing commitment to its core medical technology business, operating in the competitive medical imaging and diagnostics sector.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• A member of the company's board of directors participated in the private placement offering, purchasing shares and common warrants at a combined purchase price of $7.06, with an exercise price of $6.81 for the common warrants.

Stakeholder Impact

• Shareholders: Potential dilution from the issuance and future exercise of shares and warrants. Opportunity for growth through the new DAT strategy and continued development of the TAEUS device. Revised deadlines for annual meeting proposals.
• Employees: Continued operations and strategic initiatives may provide stability or new opportunities.
• Customers: Continued development of the TAEUS liver device could lead to future product availability.
• Creditors: The capital raise strengthens the company's financial position, potentially improving creditworthiness.
• Investment Professionals: New investment strategy in digital assets requires careful monitoring and evaluation due to inherent volatility.

Next Steps

• The private placement offering is expected to close on October 15, 2025.
• The company will enter into a Registration Rights Agreement on the closing date.
• The company will file a registration statement with the SEC within thirty days of the closing date to register the resale of the issued shares and warrant shares.
• The company will proceed with establishing its Digital Asset Treasury (DAT) strategy, managed by Arca Investment Management, LLC.
• The company will continue the pilot validation imaging study of its TAEUS liver device.
• The 2025 Annual Meeting of Stockholders will be held on December 9, 2025.
• Stockholder proposals and director nominations for the 2025 Annual Meeting must be submitted by October 27, 2025.

Key Dates

Recommendation

While the capital raise provides necessary funding for both the core TAEUS device development and the new digital asset treasury (DAT) strategy, the significant potential for dilution from the warrants and the high-risk, speculative nature of the DAT strategy introduce considerable uncertainty. The company is venturing into a highly volatile asset class, which could lead to substantial gains or losses. Investors should hold to observe the execution and performance of the DAT strategy and the progress of the TAEUS liver device study before making further investment decisions. The termination of the ATM agreement is a neutral event, replaced by the private placement.

Keywords

ENDRA Life Sciences, NDRA, Private Placement, Digital Asset Treasury, DAT Strategy, TAEUS Liver Device, Warrants, SEC Filing, Capital Raise, Arca Investment Management, Decentralized Finance, Cryptocurrency, Shareholder Meeting, Corporate Governance